{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:59:40Z","timestamp":1771455580883,"version":"3.50.1"},"reference-count":38,"publisher":"Becaris Publishing Limited","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Objective was to compare adherence and persistence, as well as direct healthcare costs and utilization, of ospemifene to available local estrogen therapies (LETs).\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            This retrospective database study used integrated medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims \u2013 US Database.\n            <jats:bold>Results:<\/jats:bold>\n            Ospemifene patients had significantly greater adherence and persistence compared with the other nonring LETs. Ospemifene had the lowest mean outpatient costs of any of the LET cohorts, including the estradiol vaginal ring. Total all-cause healthcare costs were also significantly less for ospemifene patients compared with all other LETs.\n          <\/jats:p>","DOI":"10.2217\/cer-2019-0091","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T11:22:47Z","timestamp":1566386567000},"page":"1111-1123","source":"Crossref","is-referenced-by-count":11,"title":["Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia"],"prefix":"10.57264","volume":"8","author":[{"given":"Brooke M","family":"Faught","sequence":"first","affiliation":[{"name":"Women\u2019s Institute of Sexual Health (WISH), Nashville, TN\u00a037212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziella","family":"Soulban","sequence":"additional","affiliation":[{"name":"Duchesnay Inc., Blainville, QC, J7C 5E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Yeaw","sequence":"additional","affiliation":[{"name":"IQVIA, San Francisco, CA 94105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Maroun","sequence":"additional","affiliation":[{"name":"Duchesnay Inc., Blainville, QC, J7C 5E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine","family":"Coyle","sequence":"additional","affiliation":[{"name":"IQVIA, Falls Church, VA 22042, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Duchesnay Inc., Blainville, QC, J7C 5E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"DeKoven","sequence":"additional","affiliation":[{"name":"IQVIA, Falls Church, VA 22042, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_2_2_2","unstructured":"The North American Menopause Society. Menopause 101: a primer for the perimenopausal (2018). https:\/\/www.menopause.org\/for-women\/menopauseflashes\/menopause-symptoms-and-treatments\/menopause-101-a-primer-for-the-perimenopausal"},{"key":"e_1_3_2_3_2","unstructured":"Mayo Clinic. Menopause (2018). https:\/\/www.mayoclinic.org\/diseases-conditions\/menopause\/symptoms-causes\/syc-20353397"},{"issue":"1","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"Mac Bride MB","year":"2010","unstructured":"Mac Bride MB , Rhodes DJ , Shuster LT . Vulvovaginal atrophy. Mayo Clin. Proc. 85(1), 87\u201394 (2010).","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/GRF.0000000000000126","article-title":"Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations","volume":"58","author":"Lev-Sagie A","year":"2015","unstructured":"Lev-Sagie A . Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin. Obstet. Gynecol. 58(3), 476\u2013491 (2015).","journal-title":"Clin. Obstet. Gynecol."},{"issue":"8","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/GME.0000000000000848","article-title":"Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR","volume":"24","author":"Kingsberg SA","year":"2017","unstructured":"Kingsberg SA , Kroll R , Goldstein I Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR. Menopause 24(8), 894\u2013899 (2017).","journal-title":"Menopause"},{"issue":"9","key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society","volume":"20","year":"2013","unstructured":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 20(9), 888\u2013902 (2013).","journal-title":"Menopause"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4137\/CMRH.S14498","article-title":"Management of vaginal atrophy: implications from the REVIVE survey","volume":"8","author":"Wysocki S","year":"2014","unstructured":"Wysocki S , Kingsberg S , Krychman M . Management of vaginal atrophy: implications from the REVIVE survey. Clin. Med. Insights Reprod. Health 8, 23\u201330 (2014).","journal-title":"Clin. Med. Insights Reprod. Health"},{"issue":"3","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jsxm.2017.01.010","article-title":"The Women\u2019s EMPOWER Survey: identifying women\u2019s perceptions on vulvar and vaginal atrophy and its treatment","volume":"14","author":"Kingsberg SA","year":"2017","unstructured":"Kingsberg SA , Krychman M , Graham S , Bernick B , Mirkin S . The Women\u2019s EMPOWER Survey: identifying women\u2019s perceptions on vulvar and vaginal atrophy and its treatment. J. Sex. Med. 14(3), 413\u2013424 (2017).","journal-title":"J. Sex. Med."},{"issue":"6","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/0092623X.2016.1208697","article-title":"The impact of a woman\u2019s dyspareunia and its treatment on her intimate partner: a qualitative analysis","volume":"43","author":"Sadownik LA","year":"2017","unstructured":"Sadownik LA , Smith KB , Hui A , Brotto LA . The impact of a woman\u2019s dyspareunia and its treatment on her intimate partner: a qualitative analysis. J. Sex Marital Ther. 43(6), 529\u2013542 (2017).","journal-title":"J. Sex Marital Ther."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/IJWH.S44579","article-title":"Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy","volume":"5","author":"Parish SJ","year":"2013","unstructured":"Parish SJ , Nappi RE , Krychman ML Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int. J. Womens Health 5, 437\u2013447 (2013).","journal-title":"Int. J. Womens Health"},{"issue":"4","key":"e_1_3_2_12_2","first-page":"281","article-title":"Sexual dysfunction in women: a practical approach","volume":"92","author":"Faubion SS","year":"2015","unstructured":"Faubion SS , Rullo JE . Sexual dysfunction in women: a practical approach. Am. Fam. Physician 92(4), 281\u2013288 (2015).","journal-title":"Am. Fam. Physician"},{"issue":"3","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.maturitas.2012.12.004","article-title":"Women\u2019s preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy","volume":"74","author":"Mattsson LA","year":"2013","unstructured":"Mattsson LA , Ericsson A , Bogelund M , Maamari R . Women\u2019s preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy. Maturitas 74(3), 259\u2013263 (2013).","journal-title":"Maturitas"},{"issue":"11","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/GME.0000000000000465","article-title":"One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy","volume":"22","author":"Portman D","year":"2015","unstructured":"Portman D , Shulman L , Yeaw J One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy. Menopause 22(11), 1197\u20131203 (2015).","journal-title":"Menopause"},{"issue":"4","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/j.esxm.2016.06.003","article-title":"What do patients want? A needs assessment of vulvodynia patients attending a vulvar diseases clinic","volume":"4","author":"LePage K","year":"2016","unstructured":"LePage K , Selk A . What do patients want? A needs assessment of vulvodynia patients attending a vulvar diseases clinic. Sex. Med. 4(4), e242\u2013e248 (2016).","journal-title":"Sex. Med."},{"issue":"7","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jsm.12190","article-title":"Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey","volume":"10","author":"Kingsberg SA","year":"2013","unstructured":"Kingsberg SA , Wysocki S , Magnus L , Krychman ML . Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J. Sex. Med. 10(7), 1790\u20131799 (2013).","journal-title":"J. Sex. Med."},{"issue":"2","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/GME.0000000000001194","article-title":"WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history","volume":"26","author":"Kingsberg SA","year":"2019","unstructured":"Kingsberg SA , Larkin L , Krychman M , Parish SJ , Bernick B , Mirkin S . WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause 26(2), 124\u2013131 (2019).","journal-title":"Menopause"},{"key":"e_1_3_2_18_2","unstructured":"Duchesnay. Ospemifene full prescribing information (2019). https:\/\/files.duchesnay.com\/duchesnay-usa\/osphena\/osphena-prescribing-information.pdf"},{"issue":"2","key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.6118\/jmm.2017.23.2.79","article-title":"Ospemifene: a novel option for the treatment of vulvovaginal atrophy","volume":"23","author":"Shin JJ","year":"2017","unstructured":"Shin JJ , Kim SK , Lee JR , Suh CS . Ospemifene: a novel option for the treatment of vulvovaginal atrophy. J. Menopausal Med. 23(2), 79\u201384 (2017).","journal-title":"J. Menopausal Med."},{"issue":"2","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/13697137.2014.975199","article-title":"The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy","volume":"18","author":"Nappi RE","year":"2015","unstructured":"Nappi RE , Panay N , Bruyniks N , Castelo-Branco C , De Villiers TJ , Simon JA . The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 18(2), 233\u2013240 (2015).","journal-title":"Climacteric"},{"issue":"6","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/GME.0000000000001292","article-title":"Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial","volume":"26","author":"Archer D","year":"2019","unstructured":"Archer D , Goldstein S , Simon JA Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. Menopause 26(6), 611\u2013621 (2019).","journal-title":"Menopause"},{"issue":"3","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal Phase III study","volume":"17","author":"Bachmann GA","year":"2010","unstructured":"Bachmann GA , Komi JO . Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal Phase III study. Menopause 17(3), 480\u2013486 (2010).","journal-title":"Menopause"},{"issue":"6","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman DJ","year":"2013","unstructured":"Portman DJ , Bachmann GA , Simon JA . Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 20(6), 623\u2013630 (2013).","journal-title":"Menopause"},{"key":"e_1_3_2_24_2","unstructured":"Premarin Prescribing Information (2018). https:\/\/www.premarinvaginalcream.com\/about"},{"key":"e_1_3_2_25_2","unstructured":"Imvexxy Prescribing Information (2018). https:\/\/www.imvexxy.com\/pi.pdf"},{"key":"e_1_3_2_26_2","unstructured":"Estrace Prescribing Information (2018). https:\/\/www.estracecream.com\/"},{"key":"e_1_3_2_27_2","unstructured":"Estring Prescribing Information (2018). http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=567"},{"key":"e_1_3_2_28_2","unstructured":"Alliance\n                            PQ\n                    . PQA adherence measures (2019). https:\/\/www.pqaalliance.org\/adherence-measures"},{"issue":"1","key":"e_1_3_2_29_2","first-page":"39","article-title":"An update on hormone replacement therapy: health and medicine for women: a multidisciplinary, evidence-based review of mid-life health concerns","volume":"84","author":"Shook LL","year":"2011","unstructured":"Shook LL . An update on hormone replacement therapy: health and medicine for women: a multidisciplinary, evidence-based review of mid-life health concerns. Yale J. Biol. Med. 84(1), 39\u201342 (2011).","journal-title":"Yale J. Biol. Med."},{"issue":"2","key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/GME.0b013e318295236f","article-title":"Clarifying Vaginal Atrophy\u2019s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners","volume":"21","author":"Simon JA","year":"2014","unstructured":"Simon JA , Nappi RE , Kingsberg SA , Maamari R , Brown V . Clarifying Vaginal Atrophy\u2019s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause 21(2), 137\u2013142 (2014).","journal-title":"Menopause"},{"issue":"10","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/GME.0000000000000319","article-title":"The North American Menopause Society recommendations for clinical care of midlife women","volume":"21","author":"Shifren JL","year":"2014","unstructured":"Shifren JL , Gass ML . The North American Menopause Society recommendations for clinical care of midlife women. Menopause 21(10), 1038\u20131062 (2014).","journal-title":"Menopause"},{"issue":"7","key":"e_1_3_2_32_2","first-page":"728","article-title":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society","volume":"24","year":"2017","unstructured":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 24(7), 728\u2013753 (2017).","journal-title":"Menopause"},{"issue":"1","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women\u2019s Health Initiative Observational Study","volume":"25","author":"Crandall CJ","year":"2018","unstructured":"Crandall CJ , Hovey KM , Andrews CA Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women\u2019s Health Initiative Observational Study. Menopause 25(1), 11\u201320 (2018).","journal-title":"Menopause"},{"issue":"10","key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women\u2019s Health Initiative Randomized Trials","volume":"318","author":"Manson JE","year":"2017","unstructured":"Manson JE , Aragaki AK , Rossouw JE Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women\u2019s Health Initiative Randomized Trials. JAMA 318(10), 927\u2013938 (2017).","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/jwh.2017.6385","article-title":"Overall safety of ospemifene in postmenopausal women from placebo-controlled Phase II and III trials","volume":"27","author":"Simon JA","year":"2018","unstructured":"Simon JA , Altomare C , Cort S , Jiang W , Pinkerton JV . Overall safety of ospemifene in postmenopausal women from placebo-controlled Phase II and III trials. J. Womens Health 27(1), 14\u201323 (2018).","journal-title":"J. Womens Health"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJWH.S41897","article-title":"Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy","volume":"5","author":"Minkin MJ","year":"2013","unstructured":"Minkin MJ , Maamari R , Reiter S . Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int. J. Womens Health 5, 133\u2013139 (2013).","journal-title":"Int. J. Womens Health"},{"issue":"1","key":"e_1_3_2_37_2","first-page":"7","article-title":"Costs of Clostridium histolyticum and fasciectomy for Dupuytren\u2019s contracture","volume":"7","author":"Donga P","year":"2015","unstructured":"Donga P , DeKoven M , Kaplan T Costs of Clostridium histolyticum and fasciectomy for Dupuytren\u2019s contracture. Am. J. Pharm. Benefits 7(1), 7\u201312 (2015).","journal-title":"Am. J. Pharm. Benefits"},{"issue":"4","key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/JOM.0b013e3182820515","article-title":"Direct and indirect costs of women diagnosed with menopause symptoms","volume":"55","author":"Kleinman NL","year":"2013","unstructured":"Kleinman NL , Rohrbacker NJ , Bushmakin AG , Whiteley J , Lynch WD , Shah SN . Direct and indirect costs of women diagnosed with menopause symptoms. J. Occup. Environ. Med. 55(4), 465\u2013470 (2013).","journal-title":"J. Occup. Environ. Med."},{"issue":"4","key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/humrep\/dev335","article-title":"The direct and indirect costs associated with endometriosis: a systematic literature review","volume":"31","author":"Soliman AM","year":"2016","unstructured":"Soliman AM , Yang H , Du EX , Kelley C , Winkel C . The direct and indirect costs associated with endometriosis: a systematic literature review. Hum. Reprod. 31(4), 712\u2013722 (2016).","journal-title":"Hum. Reprod."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2019-0091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:45:17Z","timestamp":1679229917000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2019-0091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":38,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.2217\/cer-2019-0091"],"URL":"https:\/\/doi.org\/10.2217\/cer-2019-0091","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}